跳至主要内容
临床试验/NCT01251003
NCT01251003撤回1 期

Safety of Autologous Human Umbilical Cord Blood Treatment for Traumatic Brain in Children

Charles Cox2 个研究点 分布在 1 个国家开始时间: 2011年1月1日最近更新:
适应症

试验速览

阶段
1 期
状态
撤回
发起方
Charles Cox
试验地点
2
主要终点
Determine if autologous hUCB transplantation is safe and free of infusion related toxicity.

研究概览

简要总结

The purpose of this study is to determine if it is safe to use stored autologous Human Umbilical Cord Blood (hUCB) to treat pediatric patients that sustain a severe or moderate Traumatic Brain Injury (TBI), and have not fully recovered as measured by the Glasgow Outcome Score-Expanded (GOS-EC)/Child at 6 to 18 months post-injury.

详细描述

Traumatic brain injury is the primary cause of pediatric trauma related morbidity and mortality. Currently there is no reparative therapeutic option available, and all interventions are designed to prevent injury progression or secondary brain injury. Pre-clinical data suggest that progenitor cellular infusions may reduce the severity of injury by a number of proposed mechanisms. The current study proposes a Phase 1 Safety Trial using stored autologous UCB to treat patients that sustain a severe or moderate TBI, and have not fully recovered as measured by the Glasgow Outcome Score-Expanded/Child at 6 to 18 months post-injury. We have chosen to use one bank that uses standardized processing and storage protocol to reduce cell product variability.

Families who have banked hUCB at Cord Blood Registry, Inc. (CBR), will be prospectively notified of the possibility of using their child's stored UCB if they sustain a moderate or severe TBI and have a persistent deficit at 6-18 months. Prior to enrolling in the study, patients will have their medical records, imaging studies reviewed, and a telephone interview will determine potential eligibility and exclusion criteria. If eligible, the patients will travel to Houston to undergo a medical history and physical exam, neuropsychiatric evaluation, DT-MRI imaging of the brain, and baseline laboratory evaluation. The UCB will be shipped to the Center for Cell and Gene Therapy for reanimation and characterization/determination of release criteria of the cell product (contamination-free). The UCB will be infused intravenously and the patient will be monitored as an in-patient in the Pediatric Intensive Care Unit (PICU) located within Children's Memorial Hermann Hospital for 24 hours, after which the patient will be discharged but will return the next day for a final examination. Follow-up visits will occur back at UT-Houston at 180 days, 1 year and 2 years post-infusion - these visits will include medical history and physical exam, neurological and neuropsych evaluations, and DT-MRI imaging of the brain.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Months 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Hospital admission Glasgow Coma Score between 3 and 12 at the time of injury
  • Injury occurring 6 to 18 months prior to study cord blood infusion (+/- 30 days)
  • Ability of child and caregiver to travel to Houston, and stay for at least 4 days, and to return for all Follow-up visits
  • Ability of child to understand (and speak) English
  • Child's own cord blood banked at Cord Blood Registry

排除标准

  • Inability to obtain all pertinent medical records, including pertinent physician notes, laboratory findings, and radiographic images, related to the original injury, hospitalization and rehabilitation
  • Recent radiographic evidence of extensive stroke as evidenced by >100ml lesion
  • Pre-injury history of seizure disorder and/or neurological impairment
  • Obliteration of perimesencephalic cistern on initial head CT/MRI
  • Initial hospital Intracranial Pressure (ICP) > 40
  • Unhealed fractures or wounds including osteomyelitis
  • Pneumonia, or chronic lung disease requiring oxygen
  • Spinal cord injury as diagnosed by CT or MR imaging or by clinical findings
  • Cord blood sample contamination
  • Participation in a concurrent intervention study

结局指标

主要结局

Determine if autologous hUCB transplantation is safe and free of infusion related toxicity.

时间窗: 0-21 days post cellular product infusion

次要结局

  • Determine if autologous hUCB transplantation improves post-TBI neuropsychological and imaging outcomes measures.(6 months, 12 months, 24 months post cellular product infusion)

研究者

发起方
Charles Cox
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Charles Cox

Professor

The University of Texas Health Science Center, Houston

研究点 (2)

Loading locations...

相似试验